DRIO
DarioHealth Corp.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$7.14
+2.29%Year over year
Reported trailing growth
- Revenue
- -22.6%
- EBITDA
- +15.6%
- EBIT
- —
- EPS
- +1625.0%
- Free cash flow
- +7.5%
- Operating cash flow
- +7.6%
Forward estimates
Based on analyst estimates
- Revenue
- +15.2%
- EBITDA
- -0.9%
- EPS
- —
Three-year CAGR
- Revenue
- -6.8%
- EBITDA
- +6.4%
- EBIT
- +36.5%
- Net income
- +2.4%
- EPS
- -9.5%
- Free cash flow
- +32.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026